Shares of AIM ImmunoTech whipsawed this week, surging more than 120% on June 1 before pulling back 13.4% to $0.78 the next day, as traders locked in gains from a pancreatic cancer trial milestone with no fresh catalyst to sustain the rally.
• Enrollment Beat the Clock, but the Real Test Is Months Away. AIM said it completed enrollment for its Phase 2 DURIPANC trial — testing its lead drug Ampligen combined with AstraZeneca's immunotherapy Imfinzi in metastatic pancreatic cancer patients — more than a month ahead of a July 2026 target, keeping the company on track for a December 2026 readout of its primary endpoint, Clinical Benefit Rate. That metric measures how many patients see their tumors stabilize or shrink. Historically, immunotherapy after standard chemotherapy has shown a median progression-free survival of under two months in similar trials — a brutally low bar. Beating it would matter, but investors won't know until year-end.
• A Tiny Company Burning Through Cash to Stay Listed. AIM has just 20 employees and a market cap of roughly $13 million . The company faces a June 11, 2026 deadline to meet NYSE American minimum shareholder equity requirements or risk being kicked off the exchange.
It recently reported stockholder equity of about $2.1 million as of March 31, 2026 — a $11.9 million swing from a deficit of $9.8 million at year-end 2025 — fueled by aggressive fundraising. The share count has ballooned by more than 102% in one year , diluting existing holders.
• The Fundraising Treadmill Shows No Signs of Stopping. In May alone, AIM tapped markets twice: a warrant exercise that generated roughly $4.2 million in gross proceeds , followed by a registered direct offering of 7.5 million shares at $0.325 apiece for another $2.4 million . It also issued warrants for up to 15 million additional shares, providing potential future funding but even more dilution.
Proceeds are earmarked for drug manufacturing, planned Phase 3 trial activities, and working capital.
• The Stock Still Trades Far Below Analyst Targets — for a Reason. The average 12-month price target from two analysts is $5.75, with a range of $1.50 to $10.00. But the 52-week range of $0.21 to $20.33 reveals a stock driven by speculative swings, not fundamentals. Until the December data readout proves Ampligen works in pancreatic cancer patients, today's pullback is simply the other side of yesterday's lottery ticket.